1、 Deeply cultivate the field of medical diagnosis and create a full industry chain ecosystem
JOINSTAR Biotechnology Co., จำกัด. was established in 2010 and is headquartered in Hangzhou. It is a high-tech biopharmaceutical enterprise specializing in the field of in vitro diagnostics (IVD) for the entire industry chain. The company integrates research and development, production, sales, service, and technology incubation, covering multiple fields such as POCT (real-time testing), biochemistry, immunology, molecular diagnostics, and extending to third-party testing, bioinformatics technology services, and medical device cold chain logistics, building an ecosystem strategy of “one main, two wings, and dual core drive”. At present, the company has more than 400 employees, with 60% having a bachelor’s degree or above. It has a production base of 25000 square meters and a public experimental platform of 1700 square meters, with an annual production capacity of 40 million sets of diagnostic kits.

2、 Hardcore technology platform, leading industry innovation
JOINSTAR is driven by technology as its core, and has achieved multiple results to fill industry gaps:The company has accumulated more than 30 patents, and its products have won honors such as “Zhejiang Province’s First (Set) Equipment” and “China In Vitro Diagnostic Innovation Product Gold Award”. The technology has been recognized as “international advanced level”.
3、 Global cooperation and industry recognition showcase brand strength
JOINSTAR has won widespread recognition for its outstanding innovation capabilities and market performance. Industry Honors: Selected for the “Kunpeng” Enterprise List in Linping District, Hangzhou City, and awarded titles such as “Forbes China Top 100 Potential Non listed Enterprises” and “First (Set) Product in Key Fields of Equipment Manufacturing Industry in Zhejiang Province”.
4、 Practice social responsibility and convey the power towards goodness
JOINSTAR has always been committed to the mission of “focusing on medical diagnosis and serving human health”, actively participating in public welfare undertakings: Charity Honor: Mr. Zhou Xuyi, the Chairman, was awarded the title of “Top Ten Charitable Entrepreneurs in Zhejiang”. The company has participated in public welfare projects such as “Spring Breeze Action” and “99 Public Welfare Day” for many years, spreading positive social energy.
Hangzhou CACLP (China International Laboratory Medicine and In Vitro Diagnostic Reagent Exhibition), as the largest and most influential event in the in vitro diagnostic industry in Asia, has always been committed to the mission of "connecting global technology and driving industrial upgrading". It gathers top enterprises, cutting-edge technologies, and industry elites from around the world, and creates an international platform that integrates exhibitions, forums, commerce, and cooperation. In 2024, Hangzhou CACLP will once again set sail, with digital empowerment and full industry chain coverage as its core, opening an innovative feast for the in vitro diagnostic industry!

1、 Global resource aggregation, empowering industrial ecology
Precise docking: Relying on AI intelligent algorithms, we accurately match the needs of exhibitors with over 100000 professional visitors (medical institutions, distributors, research institutions) and efficiently leverage business opportunities.
2、 Cutting edge technology trends define the future of the industry
Industry university research integration: Jointly organize the "Industry university research cooperation docking meeting" with institutions such as Zhejiang University and the Chinese Academy of Sciences to accelerate the transformation and implementation of scientific and technological achievements.
3、 Supported by Hangzhou's advantages, activate the growth engine
Location Empowerment: Based on the highland of the biopharmaceutical industry in the Yangtze River Delta, we enjoy the policy dividends and industrial cluster advantages of Hangzhou's digital economy;
4、 Upgrading the exhibition value and achieving a win-win trillion dollar market
Brand exposure: Covering over 200 industry media outlets, authoritative reports from CCTV, Xinhua News Agency, ฯลฯ, to enhance global brand awareness;